Scientists Create First Human Antibodies to Block Epstein-Barr Virus

Breakthrough Targets Near-Universal Pathogen

Scientists at Fred Hutchinson Cancer Center have achieved what researchers have pursued for decades: creating human antibodies that successfully block Epstein-Barr virus from infecting immune cells. The virus is believed to infect about 95% of people worldwide , earning it the informal nickname "Every Body's Virus." EBV has been linked to several cancers, neurodegenerative disorders, and other long term health conditions .

The research team used mice engineered with human antibody genes to generate fully human monoclonal antibodies designed to block two critical viral surface proteins . These proteins normally help EBV attach to and enter human immune cells . Previous attempts to find protective antibodies had failed because EBV has evolved a much broader ability to connect with virtually every single one of our B-cells .

The findings, published in Cell Reports Medicine, highlight one antibody in particular that protected mice with human immune systems from infection when they were exposed to EBV . In laboratory tests, one antibody directed at gp42 completely prevented EBV infection in mice with human immune systems , while an antibody against gp350 offered partial protection .

Critical Need for High-Risk Patients

The breakthrough carries particular significance for transplant recipients, who face life-threatening complications from EBV reactivation. Each year, more than 128,000 people in the U.S. receive solid organ or bone marrow transplants. These patients must take medications that suppress their immune systems to prevent rejection .

For transplant recipients—whose immune systems are deliberately weakened to prevent organ rejection—EBV can reactivate and turn deadly, triggering aggressive lymphomas that kill or disable thousands each year . While most people carry the virus harmlessly, immunocompromised patients lack the defenses to keep it in check.

EBV is linked to approximately 358,000 cases of cancer each year, resulting in about 209,000 deaths . The virus also contributes to multiple sclerosis and various autoimmune conditions, making effective treatments a global health priority.

Innovation in Antibody Engineering

The research team overcame longstanding technical barriers by developing a novel approach to antibody discovery. The Fred Hutch team innovated an experimental platform that integrates human antibody gene repertoires into mice, allowing the precise generation and selection of fully human antibodies devoid of immunogenicity concerns typical of non-human antibody therapies .

The gp350 glycoprotein facilitates EBV's initial binding to the complement receptor type 2 (CR2) on B cells, essentially the gateway to infection. Conversely, gp42 mediates the fusion process that allows EBV to merge with the host cell membrane, completing viral entry . By targeting both proteins simultaneously, researchers created a multi-layered defense system.

Further analysis found sites of vulnerability that could be useful in future vaccine development . This structural mapping provides blueprints for designing vaccines that could trigger similar protective responses in humans.

Path to Clinical Application

Fred Hutch has filed for intellectual property rights covering monoclonal antibodies identified in the study, and researchers are working with scientific collaborators and an industry partner to advance a potential therapy for immunocompromised patients. A potential therapy could be tested for safety in healthy adult volunteers and, if acceptable, proceed to clinical trials in the relevant patient population .

There's momentum to advance our discovery to a therapy that would make a huge difference for patients undergoing transplant , according to lead researcher Andrew McGuire. The approach also validates a new method for discovering protective antibodies against other challenging pathogens.

The research represents more than just a single breakthrough—it demonstrates how innovative laboratory techniques can unlock solutions to problems that have stymied scientists for generations. For the millions of people whose immune systems cannot control EBV, these findings offer the first realistic hope for targeted protection against a virus that has infected humanity since our earliest days.